iRhythm (IRTC) vs Envista (NVST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Envista (NVST) has outperformed iRhythm (IRTC) over the past year, gaining 10.4% versus a loss of 42.7%. Over five years, IRTC leads with a +41.9% price change compared with -41.3% for NVST. Envista is the larger company by market cap ($3.65 billion vs $3.38 billion), about 1.1 times the size, while iRhythm is growing revenue faster (+26.2% vs +8.3%).
On valuation, Envista trades at a lower forward P/E (13.7x vs 80.1x for iRhythm). Envista converts more of its revenue into profit, with a net margin of 1.7% versus -6.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRTC | NVST |
|---|---|---|
| Share price | $102.60 | $22.72 |
| Market cap | $3.38B | $3.65B |
| 1-day change | -2.28% | -1.39% |
| YTD return | -42.18% | +4.65% |
| 1-year return | -42.68% | +10.40% |
| 5-year return | +41.93% | -41.32% |
| P/E ratio (TTM) | — | 39.17 |
| Forward P/E | 80.06 | 13.65 |
| EPS (TTM) | $-0.42 | $0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $747.14M | $2.72B |
| Revenue growth (YoY) | +26.24% | +8.32% |
| Net income (latest FY) | $-44.55M | $47.00M |
| Gross margin | 70.57% | 54.67% |
| Operating margin | -7.68% | 7.95% |
| Net margin | -5.96% | 1.73% |
| 52-week high | $212.00 | $30.42 |
| 52-week low | $100.70 | $18.77 |
| Distance from 52-week high | -51.60% | -25.31% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +69.52% | +30.68% |
| Average volume | 567.98K | 2.77M |
| Shares outstanding | 32.96M | 160.62M |
| Employees | 2,400 | 12,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVST has outperformed IRTC by 53.1 percentage points over the past year.
- Envista is more profitable, keeping 1.7 cents of every revenue dollar as net income versus -6.0 cents for iRhythm.
- iRhythm grew revenue faster in its latest fiscal year (+26.24% vs +8.32%).
About iRhythm
IRTC stock →iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Health Care · Medical/Dental Instruments · 2,400 employees
About Envista
NVST stock →Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables.
Health Care · Medical/Dental Instruments · 12,000 employees
IRTC vs NVST FAQ
Which is bigger, iRhythm or Envista?
Envista (NVST) is larger, with a market capitalization of $3.65B compared with $3.38B for iRhythm (IRTC).
Which stock has performed better over the past year, IRTC or NVST?
NVST returned +10.40% over the past 12 months, compared with -42.68% for IRTC (price return, excluding dividends). Past performance does not predict future results.
Are iRhythm and Envista in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.